Cogent Biosciences, Inc.

As of September 19, 2025, Cogent Biosciences, Inc. shows a mildly bullish trend despite mixed signals from indicators, having underperformed the S&P 500 with a -5.45% return over the past week and -9.82% over the past year.

As of August 26, 2025, Cogent Biosciences, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite a bearish weekly RSI and mild bearishness in OBV, with a year-to-date return of 63.08% outperforming the S&P 500.

As of June 17, 2025, Cogent Biosciences, Inc. is in a mildly bearish trend, supported by daily moving averages and a bearish monthly MACD, despite some mixed signals from weekly indicators.

As of March 2022, the management team of Cogent Biosciences, Inc. includes Andrew Robbins (President and CEO), Chris Cain, Peter Harwin, Karen Ferrante, Arlene Morris, and Matthew Ros, all of whom guide the company's strategic direction and operations.

Cogent Biosciences, Inc. is a biopharmaceutical company focused on developing precision therapies for genetically defined diseases and curative cell therapies for solid tumors. It operates as a micro-cap company with a market cap of approximately $867.59 million and reported a net profit loss of $72 million in March 2025.

As of Jun 18, Cogent Biosciences, Inc. has a market capitalization of 867.59 million and reported net sales of 0.00 million with a net profit of -269.50 million over the last four quarters. Shareholder's funds were 256.29 million, and total assets amounted to 327.90 million as of Dec 24.